A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

Starting soon · Phase 1/Phase 2

Conditions studied: Arthritis, Rheumatoid

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).

Key facts

Study ID

NCT07412704

Run by

Bristol-Myers Squibb

People needed

84

Starts

2026-09-15

Expected to finish

2030-09-02

Last updated by the study team

2026-07-17

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat.

You may not qualify if…

• Juvenile arthritis or onset of inflammatory arthritis before age 18.
• Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out.
• Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Where it is running

• Local Institution - 0068 — La Jolla, California, United States
• Local Institution - 0070 — Loma Linda, California, United States
• Local Institution - 0069 — Palo Alto, California, United States
• Local Institution - 0050 — Aurora, Colorado, United States
• Local Institution - 0067 — Denver, Colorado, United States
• Local Institution - 0055 — South Miami, Florida, United States
• Local Institution - 0081 — New York, New York, United States
• Local Institution - 0079 — New York, New York, United States
• Local Institution - 0066 — Portland, Oregon, United States
• Local Institution - 0071 — Philadelphia, Pennsylvania, United States
• Local Institution - 0051 — DeSoto, Texas, United States
• Local Institution - 0057 — San Antonio, Texas, United States
• Local Institution - 0048 — Merksem, Flanders, Belgium
• Local Institution - 0049 — Leuven, Belgium
• Local Institution - 0083 — Aparecida de Goiânia, Goiás, Brazil
• Local Institution - 0033 — Porto Alegre, Rio Grande do Sul, Brazil
• Local Institution - 0082 — Valinhos, São Paulo, Brazil
• Local Institution - 0006 — Beijing, Beijing Municipality, China
• Local Institution - 0080 — Guangzhou, Guangdong, China
• Local Institution - 0010 — Zhengzhou, Henan, China
• Local Institution - 0007 — Nanchang, Jiangxi, China
• Local Institution - 0020 — Shanghai, Shanghai Municipality, China
• Local Institution - 0001 — Shanghai, Shanghai Municipality, China
• Local Institution - 0040 — München, Bavaria, Germany
• Local Institution - 0022 — Berlin, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.